NCT03319667: Phase 3 - Isatuximab, Bortezomib, Lenalidomide and Dexamethasone NDMM (IMROZ)
IMROZ Study NCT03319667 Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not...
Dec 16, 2017
664
NCT03091257: Phase 1 - Dabrafenib and/or Trametinib in Patients With Relapsed Refractory Myeloma
Multiple Myeloma Research Consortium NCT03091257: Phase 1 - Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory...
Dec 15, 2017
131
NCT03106324: Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma -TNE
NCT03106324: Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant A...
Dec 15, 2017
67
NCT03236428: Phase 2: Phase II Study of the CD38 Antibody Daratumumab MGUS / Smoldering Myeloma SMM
NCT03236428: Phase 2: Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple...
Dec 15, 2017
180
NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma
NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma A Safety, PK and Efficacy Study of...
Dec 15, 2017
284
FDA Approved for RRMM: Daratumumab + Pomalidomide & Dexamethasone
HORSHAM, PA, June 16, 2017 – Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the...
Dec 14, 2017
57
Myeloma Canada: Multiple Myeloma Patient Handbook
Myeloma Canada: Multiple Myeloma Patient Handbook https://myeloma.ca/pixms/uploads/serve/ckeditor/myeloma_canada_patient_handbook_10_2017...
Dec 14, 2017
173
Phase II HOVON 143 Study: Ixazomib, Dara and Low Dose Dex in Intermediate-Fit Patients NDMM
Phase II HOVON 143 Study Trial Update 63rd ASH Annual Meeting 80 Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit...
Dec 14, 2017
283
NCT03346135: Phase 2: Daratumumab After Stem Cell Transplant in Treating Patients With Myeloma NDMM
Multiple Myeloma Research Consortium NCT03346135: Phase 2: Daratumumab After Stem Cell Transplant in Treating Patients With Multiple...
Dec 14, 2017
59
NCT03104842: Phase 2 - GMMG - CONCEPT - Eval. iNduction, Consol. & Maint. Isatuximab Carf Len. & Dex
GMMG - The German Speaking Myeloma Multicenter Group GMMG-CONCEPT trial Isa-KRd NCT03104842: Phase 2 - Evaluation iNduction,...
Dec 14, 2017
267
Cleveland Clinic: How to Give Subcutaneous Chemotherapy Injections
Cleveland Clinic: How to Give Subcutaneous Chemotherapy Injections
Dec 14, 2017
114
NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With RRMM
NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) A Phase...
Dec 14, 2017
357
NCT03318861: Phase 1: Study to Evaluate the Safety and Efficacy of KITE-585 in RRMM Multiple Myeloma
NCT03318861: Phase 1: Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma...
Dec 13, 2017
30
NCT03338972: Phase 1 - Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 in RRMM
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma NCT03338972: Phase 1...
Dec 13, 2017
292
NCT03288493: Phase 1/2 - P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Myeloma
(PRIME) NCT03288493: Phase 1/2 - P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) NCT03288493: Phase...
Dec 13, 2017
132
NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma MajesTEC1
MajesTEC1 Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory...
Dec 12, 2017
385
NCT03218683: Phase 1/2: Study of AZD5991 Alone or with Venetoclax in Relapsed Hem Malignancies
NCT03218683: Phase 1/2: Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies....
Dec 10, 2017
89
NCT03275285: Phase 3 - Isatuximab, Carf & Dex VS Carf And Dex In Relapse Multiple Myeloma (IKEMA)
IKEMA Isa-Kd Vs Kd Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In...
Dec 10, 2017
474
NCT03119363: Treating Cancer-Related Fatigue Through Systematic Light Exposure
Cancer related fatigue (CRF) is the most common cancer side effect and can severely interfere with activities of daily living long after...
Dec 9, 2017
119
Penn Medicine, the Abramson Cancer Center: CAR-T Cell Therapy: Using Healthy Cells to Fight Cancer
Penn Medicine, the Abramson Cancer Center: CAR-T Cell Therapy: Using Healthy Cells to Fight Cancer Learn more:...
Dec 9, 2017
136
NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma
NCT03269136 MAGNETISMM-1 RRMM NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma To...
Dec 9, 2017
507
SITC - Society for Immunotherapy of Cancer IMMUNOTHERAPY: The Path to a Cancer Cure
SITC - Society for Immunotherapy of Cancer IMMUNOTHERAPY: The Path to a Cancer Cure (For Patients) Learn more: Society for Immunotherapy...
Dec 9, 2017
116
Roswell Park - REVLIMID (Lenalidomide) Maintenance Therapy Approved for Multiple Myeloma Patients
Roswell Park Comprehensive Cancer Center REVLIMID (Lenalidomide) Maintenance Therapy Approved for Multiple Myeloma Patients Feb 23, 2017...
Dec 9, 2017
83
NCT03078452: Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy - Multiple Myeloma
NCT03078452: Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy...
Dec 9, 2017
64